Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
Provided By GlobeNewswire
Last update: Oct 1, 2025
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform -
- Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market -
Read more at globenewswire.com
